Baseline Characteristics According To Gender In A Large Exacerbations Trial

Vogelmeier, Claus; Beeh, Kai-Michael; Mölken, Maureen Rutten-van; Glaab, Thomas; Schmidt, Hendrik; Hederer, Bettina

doi:10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a4495

Cited by 3 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13,14 The results are also consistent with an RCT that demonstrated comparable cardiovascular event rates in individuals with COPD taking LABAs and LAAs in its secondary safety analysis. 16 Finally, the results are consistent with our own previous study 15 in which the comparative association of LABAs and LAAs on the composite outcome of death, hospitalization, or an emergency department visit for COPD or a related respiratory disease was decreased when a hospitalization or an emergency department visit for cardiovascular disease was added to the outcome. Our study also found significantly increased cardiovascular risk associated with the new use of LABAs and the new use of LAAs relative to nonuse of either drug.…”

Section: Discussionsupporting

confidence: 89%

See 1 more Smart Citation

Cardiovascular Safety of Inhaled Long-Acting Bronchodilators in Individuals With Chronic Obstructive Pulmonary Disease

et al. 2013

View full text Add to dashboard Cite

IMPORTANCE Chronic obstructive pulmonary disease (COPD) is a common and deadly disease. Long-acting inhaled β-agonists and anticholinergics, first-line medications for COPD, have been associated with increased risk of cardiovascular outcomes. When choosing between the medications, patients and physicians would benefit from knowing which has the least risk. OBJECTIVE To assess the association of these classes of medications with the risk of hospitalizations and emergency department visits for cardiovascular events. DESIGN We conducted a nested case-control analysis of a retrospective cohort study. We compared the risk of events between patients newly prescribed inhaled long-acting β-agonists and anticholinergics, after matching and adjusting for prognostic factors. SETTING Health care databases from Ontario, the largest province of Canada, with a multicultural population of approximately 13 million. PARTICIPANTS All individuals 66 years or older meeting a validated case definition of COPD, based on health administrative data, and treated for COPD from September 1, 2003, through March 31, 2009. EXPOSURE New use of an inhaled long-acting β-agonist or long-acting anticholinergic. MAIN OUTCOME AND MEASURES An emergency department visit or a hospitalization for a cardiovascular event. RESULTS Of 191 005 eligible patients, 53 532 (28.0%) had a hospitalization or an emergency department visit for a cardiovascular event. Newly prescribed long-acting inhaled β-agonists and anticholinergics were associated with a higher risk of an event compared with nonuse of those medications (respective adjusted odds ratios, 1.31 [95% CI, 1.12-1.52; P < .001] and 1.14 [1.01-1.28; P = .03]). We found no significant difference in events between the 2 medications (adjusted odds ratio of long-acting inhaled β-agonists compared with anticholinergics, 1.15 [95% CI, 0.95-1.38; P = .16]). CONCLUSIONS AND RELEVANCE Among older individuals with COPD, new use of long-acting β-agonists and anticholinergics is associated with similar increased risks of cardiovascular events. Close monitoring of COPD patients requiring long-acting bronchodilators is needed regardless of drug class.

show abstract

Section: Discussionsupporting

confidence: 89%

“…6 Given their similar effectiveness, knowing which medicine has the least risk is important to making informed decisions. 15,16 We conducted the present study to clarify the relative cardiovascular risk of LABA compared with LAA in older patients with COPD.…”

mentioning

confidence: 99%

Cardiovascular Safety of Inhaled Long-Acting Bronchodilators in Individuals With Chronic Obstructive Pulmonary Disease

et al. 2013

View full text Add to dashboard Cite

show abstract

“…92 In a randomized, controlled, multicenter, international trial, 7376 patients with moderate to very severe COPD who had experienced at least 1 exacerbation in the previous year were treated with either tiotropium bromide or salmeterol for 12 months. 93 Tiotropium bromide was more effective than salmeterol in increasing the time to first COPD exacerbation (trial primary outcome measure) (tiotropium, 187 days; salmeterol, 145 days, corresponding to a 17% reduction in risk with tiotropium (HR, 0.83; 95% CI, 0.77−0.90; p < 0.001), in increasing the time to first severe exacerbation, and in reducing the number of moderate or severe exacerbations during the 12-month study period. 93 No significant differences in mortality or adverse events were observed between the treatment groups.…”

Section: Journal Of Medicinal Chemistrymentioning

confidence: 99%

“…93 Tiotropium bromide was more effective than salmeterol in increasing the time to first COPD exacerbation (trial primary outcome measure) (tiotropium, 187 days; salmeterol, 145 days, corresponding to a 17% reduction in risk with tiotropium (HR, 0.83; 95% CI, 0.77−0.90; p < 0.001), in increasing the time to first severe exacerbation, and in reducing the number of moderate or severe exacerbations during the 12-month study period. 93 No significant differences in mortality or adverse events were observed between the treatment groups. 93 Data on pulmonary function were not provided in this study.…”

Section: Journal Of Medicinal Chemistrymentioning

confidence: 99%

Bronchodilating Drugs for Chronic Obstructive Pulmonary Disease: Current Status and Future Trends

Montuschi

Ciabattoni

2015

J. Med. Chem.

View full text Add to dashboard Cite

Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and long-acting β2-adrenoreceptor agonists (LABA), are the mainstay of pharmacological treatment of stable chronic obstructive pulmonary disease (COPD). Among approved LAMA, tiotropium bromide, glycopyrronium bromide, and umeclidinium bromide are administered once daily, whereas aclidinium bromide is administered every 12 h. New LAMA are under development for COPD. Among the approved LABA, indacaterol has a 24 h duration of action, whereas salmeterol and formoterol require twice-daily administration. New once-daily LABA, including vilanterol, olodaterol, milveterol, carmoterol, and abediterol, are in development. LAMA/LABA fixed dose combinations (FDCs) provide the convenience of two bronchodilators with different mechanism of action in a single inhaler. Indacaterol/glycopyrronium, umeclidinium/vilanterol, and olodaterol/tiotropium FDCs have been approved or are under approval and are likely to become a standard pharmacological strategy for COPD. Inhaled dual-pharmacology compounds, combining muscarinic antagonism and β2-agonism (MABA) in a single molecule, potentially provide additive or synergistic bronchodilation over either inhaled antimuscarinic or β2-agonist monotherapy.

show abstract

“…Pharmacotherapy in COPD includes various groups of bronchodilators and anti-inflammatory therapies. To date, pharmacotherapy in COPD has failed to show a direct impact on survival but does importantly reduce symptoms, exacerbation frequency and improves overall health status, with relatively weak evidence for lung function improvements (26,58,(127)(128)(129)(130). Therefore, current guidelines advocate treatment based on a patients symptoms and exacerbation risk (38).…”

Section: Pharmacological Treatment Of Copdmentioning

confidence: 99%

Clinical, immunological and microbiological phenotypes of chronic obstructive pulmonary disease (COPD) in ethnic Chinese populations in South-East Asia

Tiew¹

View full text Add to dashboard Cite

show abstract

Baseline Characteristics According To Gender In A Large Exacerbations Trial

Cited by 3 publications

References 0 publications

Cardiovascular Safety of Inhaled Long-Acting Bronchodilators in Individuals With Chronic Obstructive Pulmonary Disease

Cardiovascular Safety of Inhaled Long-Acting Bronchodilators in Individuals With Chronic Obstructive Pulmonary Disease

Bronchodilating Drugs for Chronic Obstructive Pulmonary Disease: Current Status and Future Trends

Clinical, immunological and microbiological phenotypes of chronic obstructive pulmonary disease (COPD) in ethnic Chinese populations in South-East Asia

Contact Info

Product

Resources

About